{"product_id":"resmed-swot-analysis","title":"ResMed SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eResMed’s strengths in advanced sleep and respiratory devices, strong recurring-revenue models, and global distribution position it well against regulatory and competitive pressures, while innovation and telehealth integration are key growth drivers and potential risks to monitor; purchase the full SWOT analysis to access a detailed, research-backed report and editable Excel tools that empower strategic decisions and investor-grade presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Share in Sleep Disordered Breathing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed holds roughly 60%–65% share of the global CPAP\/APAP market in 2025 after Philips' long absence, creating an installed base exceeding 20 million devices that generates recurring consumable revenue—masks, tubing, filters—estimated at ~$1.2 billion annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Digital Health and Informatics Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed shifted from devices to digital health with AirView and myAir, powering over 18 million cloud‑connectable devices as of Dec 2025 and capturing trillions of sleep and therapy data points to raise adherence; in FY2025 software and SaaS offerings contributed about 28% of revenue (~$1.9B), driving better clinical outcomes and lowering hospitalization risk; integrated workflows create strong switching costs for providers tied into its ecosystem.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Performance and High Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed posts gross margins around 60% and operating margins near 20%, well above the med-tech median; these high margins reflect pricing power in sleep and respiratory care. As of Q3 2025, ResMed held about $2.8 billion in cash and generated trailing‑12‑month free cash flow of roughly $1.1 billion, funding R\u0026amp;D spend near $460 million YTD. This strong cash flow cushions macro risk and supports disciplined M\u0026amp;A and capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Intellectual Property and Innovation Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed holds over 4,500 granted patents and thousands pending across flow generators, masks, and respiratory algorithms, creating a strong barrier to entry for competitors.\u003c\/p\u003e\n\u003cp\u003eResMed invested about $460 million in R\u0026amp;D in FY2024, keeping it ahead on mask comfort and device quietness—key drivers of patient compliance and adherence.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 ResMed’s latest devices cut size and weight by ~18% and added low-power Bluetooth\/5G connectivity, setting new benchmarks for portability and remote monitoring.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4,500+ granted patents\u003c\/li\u003e\n\u003cli\u003e$460M R\u0026amp;D FY2024\u003c\/li\u003e\n\u003cli\u003e~18% smaller\/lighter by 2025\u003c\/li\u003e\n\u003cli\u003eBluetooth\/5G connectivity, enhanced algorithms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Recognition and Clinical Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed is seen by sleep physicians and respiratory therapists as the gold standard for clinical efficacy and device reliability, backed by 200+ peer-reviewed studies through 2025 that drive clinical adoption.\u003c\/p\u003e\n\u003cp\u003eThat deep evidence base and brand trust make it hard for low-cost rivals to displace ResMed, supporting higher pricing and faster uptake for new respiratory products.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ peer-reviewed studies (through 2025)\u003c\/li\u003e\n\u003cli\u003ePremium pricing sustained vs low-cost rivals\u003c\/li\u003e\n\u003cli\u003eStronger point-of-care patient preference\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed: CPAP Leader—65% Share, $1.9B SaaS, \u0026gt;20M Devices, $1.1B FCF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed dominates CPAP with ~60–65% share in 2025, \u0026gt;20M installed devices and recurring consumables ≈$1.2B\/yr; software\/SaaS ~28% revenue (~$1.9B FY2025) with \u0026gt;18M cloud devices; gross margin ≈60%, TTM FCF ~$1.1B, cash ~$2.8B; 4,500+ patents, $460M R\u0026amp;D FY2024, 200+ peer‑reviewed studies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPAP share (2025)\u003c\/td\u003e\n\u003ctd\u003e60–65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled devices\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables rev\u003c\/td\u003e\n\u003ctd\u003e$1.2B\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware\/SaaS rev FY2025\u003c\/td\u003e\n\u003ctd\u003e$1.9B (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM FCF\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$2.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e4,500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2024\u003c\/td\u003e\n\u003ctd\u003e$460M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeer‑reviewed studies\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of ResMed, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and future growth potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise ResMed SWOT matrix for rapid strategic alignment, ideal for executives seeking a clear snapshot of competitive positioning and product-market strengths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Revenue Concentration in Sleep Apnea\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite growing digital health and ventilator lines, ResMed still earns roughly 70% of FY2025 revenue from sleep-disordered breathing and CPAP-related products (FY2025 revenue $4.4B; sleep segment ≈ $3.1B), leaving the company exposed if guidelines, reimbursement, or diagnostic trends shift.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium Pricing Strategy in Price-Sensitive Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed’s premium pricing limits adoption in price-sensitive markets; in 2024 roughly 40% of global sleep apnea device demand came from emerging markets where average selling prices are 30–50% lower, per industry reports. As payers tighten budgets—US Medicare device reimbursements flat in 2023 and many EU health systems cutting procurement—ResMed risks losing entry-level share to low-cost rivals who undercut prices by 20–40%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Third-Party Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed depends heavily on Medicare and private insurers for reimbursement; a 10% cut in durable medical equipment (DME) rates would shave millions from provider purchasing power and could reduce ResMed device volumes.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Medicare DME spending fell 2.1% year-over-year, and any further downward rate adjustments would hit revenues tied to CPAP and ventilator sales.\u003c\/p\u003e\n\u003cp\u003eShifts to value-based care—projected to cover \u0026gt;40% of Medicare beneficiaries by late 2025—pressure fee-for-service equipment sales and force ResMed to prove outcomes to sustain pricing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity of SaaS Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eResMed’s acquisitions of Brightree (2016) and MatrixCare (2018) broadened its out-of-hospital SaaS footprint, but integrating disparate platforms raises operational complexity and costs — ResMed reported 2024 R\u0026amp;D and SG\u0026amp;A of US$1.2bn and US$1.8bn respectively, showing scale but integration burden.\u003c\/p\u003e\n\u003cp\u003eSoftware update friction or poor cross-platform compatibility can drive churn in a competitive healthcare IT market where median annual SaaS churn ~10% (2023), risking subscription revenue growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple platforms need distinct skills\u003c\/li\u003e\n\u003cli\u003e2024 SG\u0026amp;A\/R\u0026amp;D: US$3.0bn total\u003c\/li\u003e\n\u003cli\u003eHealthcare SaaS median churn ~10% (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong Product Development and Regulatory Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe medical device sector's heavy regulation makes ResMed's R\u0026amp;D slow and capital‑heavy; ResMed spent $418.8 million on R\u0026amp;D in FY2025 (ended Sept 30, 2025), so approval timelines materially affect cash deployment and returns.\u003c\/p\u003e\n\u003cp\u003eGlobal regulatory complexity delays launches—CE, FDA, and PMDA filings can stagger releases by months—hindering simultaneous rollouts across major markets.\u003c\/p\u003e\n\u003cp\u003eLong lead times limit ResMed's ability to match fast consumer-tech shifts in sleep and respiratory care devices, risking feature gaps versus agile digital entrants.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend FY2025: $418.8M\u003c\/li\u003e\n\u003cli\u003eRegulatory stagger: months per region\u003c\/li\u003e\n\u003cli\u003eRisk: slower response to consumer-tech trends\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSleep-focused revenue (70%) and Medicare exposure threaten growth as costs rise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh dependence on sleep\/CPAP: ~70% of FY2025 revenue (FY2025 revenue $4.4B; sleep ≈ $3.1B) risks exposure to guideline\/reimbursement shifts. Premium pricing limits share in emerging markets (~40% demand; ASPs 30–50% lower), enabling low-cost rivals to undercut by 20–40%. Heavy reliance on Medicare\/DME means reimbursement cuts (Medicare DME spending −2.1% in 2024) would hit volumes. Integration of Brightree\/MatrixCare raises SG\u0026amp;A\/R\u0026amp;D burden (FY2025 SG\u0026amp;A+R\u0026amp;D = US$3.0B) and SaaS churn risk (~10%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$4.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep segment\u003c\/td\u003e\n\u003ctd\u003e$3.1B (~70%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2025\u003c\/td\u003e\n\u003ctd\u003e$418.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A+R\u0026amp;D FY2025\u003c\/td\u003e\n\u003ctd\u003e$3.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare DME change 2024\u003c\/td\u003e\n\u003ctd\u003e−2.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare SaaS churn (median 2023)\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eResMed SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is the same file included in your download. Buy now to unlock the complete, editable version with full detail and structured insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752381624697,"sku":"resmed-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/resmed-swot-analysis.png?v=1772240282","url":"https:\/\/matrixbcg.com\/products\/resmed-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}